Custirsen Trial Fails to Show Improvement in Survival

Median OS not reached in metastatic prostate cancer treated with investigational SV-102, phase I study finds

Median overall survival has not been reached in the phase I study of SYNC-T Therapy SV-102, an investigational multi-target immunotherapy platform for solid tumors in patients with metastatic prostate cancer, as of the April 1 data cutoff.

November 06, 2026

Vol.52 No.41

Clinical Roundup

Perioperative apalutamide reduces risk of death and metastasis in high-risk localized or locally advanced prostate cancer, study finds

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

November 06, 2026

Vol.52 No.41

Clinical Roundup

Researchers identify critical window for boosting immunotherapy response in prostate cancer, Roswell Park-led study finds

A team of researchers has shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body’s immune response before those immune effects begin to fade over time.

November 06, 2026

Vol.52 No.41

Clinical Roundup

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

October 30, 2026

Vol.52 No.40

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations.

October 30, 2026

Vol.52 No.40

Custirsen Trial Fails to Show Improvement in Survival

YOU MAY BE INTERESTED IN

Median OS not reached in metastatic prostate cancer treated with investigational SV-102, phase I study finds

Perioperative apalutamide reduces risk of death and metastasis in high-risk localized or locally advanced prostate cancer, study finds

Researchers identify critical window for boosting immunotherapy response in prostate cancer, Roswell Park-led study finds

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

Renew today!

Subscriber content

Never miss an issue!

Login